TWI543981B - 作為c-kit激酶抑制劑之化合物及組合物 - Google Patents

作為c-kit激酶抑制劑之化合物及組合物 Download PDF

Info

Publication number
TWI543981B
TWI543981B TW101131940A TW101131940A TWI543981B TW I543981 B TWI543981 B TW I543981B TW 101131940 A TW101131940 A TW 101131940A TW 101131940 A TW101131940 A TW 101131940A TW I543981 B TWI543981 B TW I543981B
Authority
TW
Taiwan
Prior art keywords
pyridine
oxadiazol
imidazo
methylphenyl
carboxamide
Prior art date
Application number
TW101131940A
Other languages
English (en)
Chinese (zh)
Other versions
TW201313716A (zh
Inventor
文斯 耶
李小玲
劉小東
強 克里斯多夫 羅倫
凡倫堤那 摩堤尼
茱利葉 那巴卡
包 紐洋
漢克 麥可 詹姆士 派特拉西
Original Assignee
諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 諾華公司 filed Critical 諾華公司
Publication of TW201313716A publication Critical patent/TW201313716A/zh
Application granted granted Critical
Publication of TWI543981B publication Critical patent/TWI543981B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW101131940A 2011-09-01 2012-08-31 作為c-kit激酶抑制劑之化合物及組合物 TWI543981B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01

Publications (2)

Publication Number Publication Date
TW201313716A TW201313716A (zh) 2013-04-01
TWI543981B true TWI543981B (zh) 2016-08-01

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101131940A TWI543981B (zh) 2011-09-01 2012-08-31 作為c-kit激酶抑制劑之化合物及組合物

Country Status (42)

Country Link
US (1) US9199981B2 (https=)
EP (1) EP2751102B1 (https=)
JP (1) JP6117208B2 (https=)
KR (1) KR101959590B1 (https=)
CN (1) CN103764653B (https=)
AP (1) AP2014007494A0 (https=)
AR (1) AR087752A1 (https=)
AU (1) AU2012300248B2 (https=)
BR (1) BR112014004504B1 (https=)
CA (1) CA2845159C (https=)
CL (1) CL2014000494A1 (https=)
CO (1) CO6900140A2 (https=)
CR (1) CR20140106A (https=)
CU (1) CU20140023A7 (https=)
CY (1) CY1121695T1 (https=)
DK (1) DK2751102T3 (https=)
EA (1) EA024293B1 (https=)
ES (1) ES2732671T3 (https=)
GT (1) GT201400036A (https=)
HR (1) HRP20191140T1 (https=)
HU (1) HUE044373T2 (https=)
IL (1) IL231226A (https=)
JO (1) JOP20120246B1 (https=)
LT (1) LT2751102T (https=)
MA (1) MA35459B1 (https=)
ME (1) ME03395B (https=)
MX (1) MX342329B (https=)
MY (1) MY167245A (https=)
PE (1) PE20141033A1 (https=)
PH (1) PH12014500351B1 (https=)
PL (1) PL2751102T3 (https=)
PT (1) PT2751102T (https=)
RS (1) RS59025B1 (https=)
SG (1) SG2014011050A (https=)
SI (1) SI2751102T1 (https=)
TN (1) TN2014000061A1 (https=)
TR (1) TR201909189T4 (https=)
TW (1) TWI543981B (https=)
UA (1) UA110841C2 (https=)
UY (1) UY34300A (https=)
WO (1) WO2013033070A1 (https=)
ZA (1) ZA201401113B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
CA2932482A1 (en) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Aryl- and hetaryl-substituted imidazo[1,2-a]pyridine-3-carboxamides and use thereof
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
UA125171C2 (uk) 2015-07-02 2022-01-26 Янссен Саєнсиз Айрленд Юсі Антибактеріальні сполуки
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
US20200308169A1 (en) 2016-06-16 2020-10-01 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
JP2019518046A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
KR20190121315A (ko) 2017-03-01 2019-10-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 병용 요법
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
MA55976A (fr) * 2019-05-13 2022-03-23 Novartis Ag Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide
US20220340564A1 (en) 2019-09-13 2022-10-27 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
DK4122923T3 (da) * 2020-03-17 2025-12-15 Sumitomo Pharma Co Ltd Oxadiazolderivat
JP2023534963A (ja) * 2020-07-15 2023-08-15 サード ハーモニック バイオ, インコーポレイテッド 選択的c-kitキナーゼ阻害剤の結晶質形態
US20220175740A1 (en) * 2020-11-19 2022-06-09 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
MX2023010947A (es) 2021-03-16 2023-11-29 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
EP4423097A1 (en) 2021-10-28 2024-09-04 Janssen Sciences Ireland Unlimited Company Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2025540958A (ja) 2022-11-30 2025-12-17 ブループリント メディシンズ コーポレイション 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体
AU2023390239A1 (en) * 2022-12-07 2025-07-24 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
US20250042898A1 (en) * 2023-07-25 2025-02-06 Enanta Pharmaceuticals, Inc. Pharmaceutical Compounds And Compositions As c-Kit Kinase Inhibitors
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
TW202542157A (zh) * 2024-01-04 2025-11-01 大陸商上海翰森生物醫藥科技有限公司 多環類衍生物抑制劑、其製備方法和應用
WO2025256552A1 (zh) * 2024-06-11 2025-12-18 上海翰森生物医药科技有限公司 吡唑类衍生物抑制剂、其制备方法和应用
WO2025259929A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
CN121181581A (zh) * 2024-06-21 2025-12-23 上海美悦生物科技发展有限公司 一种稠杂环化合物、其制备方法和用途
CN121426815A (zh) * 2024-07-30 2026-01-30 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途
WO2026032333A1 (zh) * 2024-08-06 2026-02-12 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2008058037A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2011329233A1 (en) * 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
US20150051206A1 (en) * 2011-09-01 2015-02-19 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CN103797011B (zh) * 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
EA201490537A1 (ru) * 2011-09-01 2014-07-30 АйАрЭм ЭлЭлСи СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit

Also Published As

Publication number Publication date
EA201490540A1 (ru) 2014-06-30
RS59025B1 (sr) 2019-08-30
GT201400036A (es) 2015-06-02
SI2751102T1 (sl) 2019-08-30
UA110841C2 (uk) 2016-02-25
US20130059846A1 (en) 2013-03-07
ES2732671T3 (es) 2019-11-25
CN103764653A (zh) 2014-04-30
ZA201401113B (en) 2015-10-28
AP2014007494A0 (en) 2014-03-31
ME03395B (me) 2020-01-20
JOP20120246B1 (ar) 2022-03-14
CR20140106A (es) 2014-05-02
TN2014000061A1 (en) 2015-07-01
PH12014500351B1 (en) 2019-04-03
KR101959590B1 (ko) 2019-03-18
US9199981B2 (en) 2015-12-01
MY167245A (en) 2018-08-14
KR20140071382A (ko) 2014-06-11
PE20141033A1 (es) 2014-08-30
AR087752A1 (es) 2014-04-16
CN103764653B (zh) 2015-12-02
EP2751102A1 (en) 2014-07-09
PT2751102T (pt) 2019-07-10
TR201909189T4 (tr) 2019-07-22
BR112014004504B1 (pt) 2022-03-22
DK2751102T3 (da) 2019-07-01
PH12014500351A1 (en) 2014-04-07
CA2845159A1 (en) 2013-03-07
NZ621092A (en) 2016-06-24
CY1121695T1 (el) 2020-07-31
AU2012300248A1 (en) 2014-04-17
CU20140023A7 (es) 2014-04-24
SG2014011050A (en) 2014-08-28
PL2751102T3 (pl) 2019-09-30
JP6117208B2 (ja) 2017-04-19
LT2751102T (lt) 2019-07-10
HUE044373T2 (hu) 2019-10-28
MX2014002482A (es) 2014-11-25
AU2012300248B2 (en) 2015-08-27
CA2845159C (en) 2020-11-03
EA024293B1 (ru) 2016-09-30
UY34300A (es) 2013-04-05
WO2013033070A1 (en) 2013-03-07
IL231226A (en) 2017-03-30
MX342329B (es) 2016-09-26
IL231226A0 (en) 2014-04-30
CL2014000494A1 (es) 2014-09-05
BR112014004504A2 (pt) 2017-03-28
MA35459B1 (fr) 2014-09-01
TW201313716A (zh) 2013-04-01
CO6900140A2 (es) 2014-03-20
EP2751102B1 (en) 2019-03-27
HRP20191140T1 (hr) 2019-09-20
JP2014525444A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
TWI543981B (zh) 作為c-kit激酶抑制劑之化合物及組合物
JP6134319B2 (ja) c−kitキナーゼインヒビターとしての化合物及び組成物
US20150051206A1 (en) Compounds and compositions as c-kit kinase inhibitors
WO2013033116A1 (en) Compounds and compositions as c-kit kinase inhibitors
CA2845798A1 (en) Compounds and compositions as pdgfr kinase inhibitors
HK1193820A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193820B (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821B (en) Compounds and compositions as c-kit kinase inhibitors
NZ621092B2 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS